Lionel Galicier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lionel Galicier has a total of 381 co-authors. Here are the top co-authors by number of shared publications:
- David Boutboul
Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Imagine Institute Université Paris Cité Paris France
11 shared publications - Eric Oksenhendler
Department of Clinical Immunology Hôpital Saint‐Louis, AP‐HP Paris France
11 shared publications - Matthieu Mahévas
Service de Médecine Interne, Centre National de Référence des Cytopénies Auto‐Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP‐HP) Université Paris Est Créteil Créteil France
8 shared publications Véronique Meignin
Department of Pathology Hôpital Saint Louis, Université Paris Cité Paris France
6 shared publications- Bertrand Godeau
Department of Internal Medicine and Clinical Immunology, coordinating center of the national reference center for adult' immune cytopenias, Henri Mondor university hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Paris, France
5 shared publications Margaux Garzaro
INSERM U976 HIPI, équipe INSIGHT, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France
5 shared publications
Latest Publications
- Open Access
- 23 December 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (24) , 6590-6592
Time to redefine HHV-8 MCD and KICS criteria?
- 23 December 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (24) , 6590-6592
Open AccessTime to redefine HHV-8 MCD and KICS criteria?
- Open Access
- 15 July 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (10) , 1736-1746
Anti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP
Current triplet regimens associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab have dramatically improved the outcome of immune‐mediated thrombotic thrombocytopenic purpura (iTTP). However, nearly half of the patients require extended caplacizumab treatment (i.e., > 30 days) due to persistent ADAMTS13 deficiency, raising cost and tolerance concerns. Therefore, we investigated whether anti‐ADAMTS13 antibodies titer and their trajectory during the acute phase of the disease could predict ADAMTS13 improvement (i.e., activity ≥ 20% before day‐30 post‐TPE). From a cohort of 286 patients receiving the triplet regimen, we identified on diagnosis a cut‐off value for anti‐ADAMTS13 IgG antibodies of 90.5 U/mL, with a modest discriminating ability (AUC: 0.57) for predicting long‐term response, precluding its use to guide therapeutic strategies. Nonetheless, the analysis of anti‐ADAMTS13 IgG antibodies titer trajectory from diagnosis revealed that the proportion of iTTP patients with ADAMTS13 activity improvement was higher in patients who decreased (Dec+) their antibodies titer within the 7–14 days interval post‐TPE compared to those without decrease (Dec−) (65% vs. 25% of cases, respectively, p < 0.001), a finding confirmed in a validation cohort ( N = 51). These results highlight the possibility of intensifying immunosuppression in an early period post‐TPE to shorten time to ADAMTS13 activity recovery. Close monitoring of anti‐ADAMTS13 antibodies titer may guide immunomodulation strategies, including additional courses of B‐cell depleting agents when appropriate.
- 15 July 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (10) , 1736-1746
Open AccessAnti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP
Current triplet regimens associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab have dramatically improved the outcome of immune‐mediated thrombotic thrombocytopenic purpura (iTTP). However, nearly half of the patients require extended caplacizumab treatment (i.e., > 30 days) due to persistent ADAMTS13 deficiency, raising cost and tolerance concerns. Therefore, we investigated whether anti‐ADAMTS13 antibodies titer and their trajectory during the acute phase of the disease could predict ADAMTS13 improvement (i.e., activity ≥ 20% before day‐30 post‐TPE). From a cohort of 286 patients receiving the triplet regimen, we identified on diagnosis a cut‐off value for anti‐ADAMTS13 IgG antibodies of 90.5 U/mL, with a modest discriminating ability (AUC: 0.57) for predicting long‐term response, precluding its use to guide therapeutic strategies. Nonetheless, the analysis of anti‐ADAMTS13 IgG antibodies titer trajectory from diagnosis revealed that the proportion of iTTP patients with ADAMTS13 activity improvement was higher in patients who decreased (Dec+) their antibodies titer within the 7–14 days interval post‐TPE compared to those without decrease (Dec−) (65% vs. 25% of cases, respectively, p < 0.001), a finding confirmed in a validation cohort ( N = 51). These results highlight the possibility of intensifying immunosuppression in an early period post‐TPE to shorten time to ADAMTS13 activity recovery. Close monitoring of anti‐ADAMTS13 antibodies titer may guide immunomodulation strategies, including additional courses of B‐cell depleting agents when appropriate.
- Open Access
- 14 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (8) , 1976-1983
Efficacy and safety of dapsone in adult primary immune thrombocytopenia
To assess efficacy and safety of dapsone in adult immune thrombocytopenia (ITP), a multicenter randomized controlled trial (RCT) and a real-world cohort study were performed. Participants were adults with primary ITP, transient response to corticosteroids with/without intravenous immunoglobulin, and a platelet count of ≤30 × 109/L (or ≤50 × 109/L with bleeding). Patients in the RCT were randomized in arm A (prednisone × 3 weeks + dapsone for 12 months) or arm B (prednisone alone). The observational study involved dapsone initiation at 100 mg/d with standard follow-up. The primary end point was the response rate (platelet count of >30 × 109/L and ≥2× baseline level) at 52 weeks, with the response rate at 24 weeks and adverse events as secondary end points. The RCT enrolled 93 patients (54.8% female), with median age of 48.5 years (46 years in arm A; and 47 years in arm B). In the intention-to-treat analysis, 78.3% of patients in arm A discontinued dapsone after a median of 4.6 weeks because of adverse events (66.7%) or lack of efficacy (33.3%). The response rate at week 52 was 21.7% (95% confidence interval [CI], 10.9-36.4) in arm A vs 8.5% (95% CI, 2.7-18.6) in arm B (P = .17). The observational study, which was conducted after the end of the RCT, included 46 patients (52.2% female), median age of 50.7 years. Adverse events occurred in 30.4%, leading to discontinuation of dapsone in 23.9%, and 13.6% (95% CI 5.2-27.4) met the primary efficacy end point. Results from both studies showed an unfavorable risk-benefit ratio for the use of dapsone in adult primary ITP and suggest that, whenever available, second-line options should be used. This trial was registered at www.ClinicalTrials.gov as #NCT02627417 and #NCT02877706.
- 14 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (8) , 1976-1983
Open AccessEfficacy and safety of dapsone in adult primary immune thrombocytopenia
To assess efficacy and safety of dapsone in adult immune thrombocytopenia (ITP), a multicenter randomized controlled trial (RCT) and a real-world cohort study were performed. Participants were adults with primary ITP, transient response to corticosteroids with/without intravenous immunoglobulin, and a platelet count of ≤30 × 109/L (or ≤50 × 109/L with bleeding). Patients in the RCT were randomized in arm A (prednisone × 3 weeks + dapsone for 12 months) or arm B (prednisone alone). The observational study involved dapsone initiation at 100 mg/d with standard follow-up. The primary end point was the response rate (platelet count of >30 × 109/L and ≥2× baseline level) at 52 weeks, with the response rate at 24 weeks and adverse events as secondary end points. The RCT enrolled 93 patients (54.8% female), with median age of 48.5 years (46 years in arm A; and 47 years in arm B). In the intention-to-treat analysis, 78.3% of patients in arm A discontinued dapsone after a median of 4.6 weeks because of adverse events (66.7%) or lack of efficacy (33.3%). The response rate at week 52 was 21.7% (95% confidence interval [CI], 10.9-36.4) in arm A vs 8.5% (95% CI, 2.7-18.6) in arm B (P = .17). The observational study, which was conducted after the end of the RCT, included 46 patients (52.2% female), median age of 50.7 years. Adverse events occurred in 30.4%, leading to discontinuation of dapsone in 23.9%, and 13.6% (95% CI 5.2-27.4) met the primary efficacy end point. Results from both studies showed an unfavorable risk-benefit ratio for the use of dapsone in adult primary ITP and suggest that, whenever available, second-line options should be used. This trial was registered at www.ClinicalTrials.gov as #NCT02627417 and #NCT02877706.
- 9 January 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (2) , 244-247
Long-term follow-up of the STOPAGO study
In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation.
- 9 January 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (2) , 244-247
Long-term follow-up of the STOPAGO study
In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation.
- Open Access
- 23 May 2023
- Published by Wiley in British Journal of Haematology
- Vol. 202 (2) , 267-278
Paraneoplastic pemphigus uncovers distinct clinical and biological phenotypes of western unicentric Castleman disease
Summary: Unicentric Castleman disease (UCD) is a lymphoproliferative disease of unknown cause. Paraneoplastic pemphigus (PNP) is a major complication shown to be associated with a poor prognosis, with particular severity in patients with bronchiolitis obliterans (BO). This study describes the clinical and biological characteristics of UCD‐PNP patients in a large Western cohort. A total of 148 patients diagnosed with UCD were identified, including 14 patients with a defined PNP. PNP was significantly associated with myasthenia gravis (MG) and FDC sarcoma during follow‐up (FDCS). PNP was also significantly associated with reduced survival. These data, together with a multivariate analysis by principal components, led to the identification of UCD‐PNP as a group at risk of MG, FDCS and death. PDGFRB sequencing performed on UCD lesions from six patients found the gain‐of‐function p.N666S variant in two. Interestingly, both patients had hyaline‐vascular UCD subtype, were in the UCD‐PNP subgroup and had FDCS. Sera from 25 UCD‐PNP patients and 6 PNP patients without UCD were tested for PNP‐associated autoantibodies. Sera from UCD‐PNP patients had a strong reactivity against the N‐terminal domain of recombinant periplakin (rPPL, 82%) and showed reactivity against at least two domains of rPPL. These features were not found in patients with UCD alone or in the PNP group without UCD. These data indicate that UCD‐PNP patients belong to a subgroup sharing strong clinical and biological identity that might help to decipher the different dynamics of UCD natural history.
- 23 May 2023
- Published by Wiley in British Journal of Haematology
- Vol. 202 (2) , 267-278
Open AccessParaneoplastic pemphigus uncovers distinct clinical and biological phenotypes of western unicentric Castleman disease
Summary: Unicentric Castleman disease (UCD) is a lymphoproliferative disease of unknown cause. Paraneoplastic pemphigus (PNP) is a major complication shown to be associated with a poor prognosis, with particular severity in patients with bronchiolitis obliterans (BO). This study describes the clinical and biological characteristics of UCD‐PNP patients in a large Western cohort. A total of 148 patients diagnosed with UCD were identified, including 14 patients with a defined PNP. PNP was significantly associated with myasthenia gravis (MG) and FDC sarcoma during follow‐up (FDCS). PNP was also significantly associated with reduced survival. These data, together with a multivariate analysis by principal components, led to the identification of UCD‐PNP as a group at risk of MG, FDCS and death. PDGFRB sequencing performed on UCD lesions from six patients found the gain‐of‐function p.N666S variant in two. Interestingly, both patients had hyaline‐vascular UCD subtype, were in the UCD‐PNP subgroup and had FDCS. Sera from 25 UCD‐PNP patients and 6 PNP patients without UCD were tested for PNP‐associated autoantibodies. Sera from UCD‐PNP patients had a strong reactivity against the N‐terminal domain of recombinant periplakin (rPPL, 82%) and showed reactivity against at least two domains of rPPL. These features were not found in patients with UCD alone or in the PNP group without UCD. These data indicate that UCD‐PNP patients belong to a subgroup sharing strong clinical and biological identity that might help to decipher the different dynamics of UCD natural history.
- Open Access
- 26 April 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (9) , 1682-1691
Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease
Kaposi sarcoma–associated herpesvirus (KSHV)/human herpesvirus 8–associated multicentric Castleman disease (MCD) is a polyclonal B-cell lymphoproliferative disorder that mainly occurs in immunocompromised hosts. The diagnosis relies on lymph node biopsy demonstrating KSHV-infected cells located in the mantle zone with a marked interfollicular plasma cell infiltration. Infected cells are large cells positive for immunoglobulin M (IgM), λ light chain, and CD38, described initially as infected plasmablasts. We show that IgM+λ+CD38high cells were also detectable in the peripheral blood of 14 out of 18 (78%) patients with active KSHV-MCD and absent in 40 controls. Using immunofluorescence and flow–fluorescence in situ hybridization, we demonstrate that these cells are KSHV infected and express both latent and lytic KSHV transcripts. These KSHV-infected viroblasts (KIVs) harbor a distinct phenotype compared with conventional plasmablasts. We also identified several putative mechanisms of immune escape used by KSHV, because KIVs displayed an overall decrease of costimulatory molecules, with a remarkable lack of CD40 expression and are interleukin-10–producing cells. The identification of this specific and easily accessible KSHV+ circulating population brings new elements to the understanding of KSHV-MCD but also raises new questions that need to be clarified.
- 26 April 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (9) , 1682-1691
Open AccessCharacteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease
Kaposi sarcoma–associated herpesvirus (KSHV)/human herpesvirus 8–associated multicentric Castleman disease (MCD) is a polyclonal B-cell lymphoproliferative disorder that mainly occurs in immunocompromised hosts. The diagnosis relies on lymph node biopsy demonstrating KSHV-infected cells located in the mantle zone with a marked interfollicular plasma cell infiltration. Infected cells are large cells positive for immunoglobulin M (IgM), λ light chain, and CD38, described initially as infected plasmablasts. We show that IgM+λ+CD38high cells were also detectable in the peripheral blood of 14 out of 18 (78%) patients with active KSHV-MCD and absent in 40 controls. Using immunofluorescence and flow–fluorescence in situ hybridization, we demonstrate that these cells are KSHV infected and express both latent and lytic KSHV transcripts. These KSHV-infected viroblasts (KIVs) harbor a distinct phenotype compared with conventional plasmablasts. We also identified several putative mechanisms of immune escape used by KSHV, because KIVs displayed an overall decrease of costimulatory molecules, with a remarkable lack of CD40 expression and are interleukin-10–producing cells. The identification of this specific and easily accessible KSHV+ circulating population brings new elements to the understanding of KSHV-MCD but also raises new questions that need to be clarified.
- Open Access
- 14 March 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (6)
A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency
Here, we report on a heterozygous interferon regulatory factor 4 (IRF4) missense variant identified in three patients from a multigeneration family with hypogammaglobulinemia. Patients’ low blood plasmablast/plasma cell and naïve CD4 and CD8 T cell counts contrasted with high terminal effector CD4 and CD8 T cell counts. Expression of the mutant IRF4 protein in control lymphoblastoid B cell lines reduced the expression of BLIMP-1 and XBP1 (key transcription factors in plasma cell differentiation). In B cell lines, the mutant IRF4 protein as wildtype was found to bind to known IRF4 binding motifs. The mutant IRF4 failed to efficiently regulate the transcriptional activity of interferon-stimulated response elements (ISREs). Rapid immunoprecipitation mass spectrometry of endogenous proteins indicated that the mutant and wildtype IRF4 proteins differed with regard to their respective sets of binding partners. Our findings highlight a novel mechanism for autosomal-dominant primary immunodeficiency through altered protein binding by mutant IRF4 at ISRE, leading to defective plasma cell differentiation.
- 14 March 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (6)
Open AccessA neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency
Here, we report on a heterozygous interferon regulatory factor 4 (IRF4) missense variant identified in three patients from a multigeneration family with hypogammaglobulinemia. Patients’ low blood plasmablast/plasma cell and naïve CD4 and CD8 T cell counts contrasted with high terminal effector CD4 and CD8 T cell counts. Expression of the mutant IRF4 protein in control lymphoblastoid B cell lines reduced the expression of BLIMP-1 and XBP1 (key transcription factors in plasma cell differentiation). In B cell lines, the mutant IRF4 protein as wildtype was found to bind to known IRF4 binding motifs. The mutant IRF4 failed to efficiently regulate the transcriptional activity of interferon-stimulated response elements (ISREs). Rapid immunoprecipitation mass spectrometry of endogenous proteins indicated that the mutant and wildtype IRF4 proteins differed with regard to their respective sets of binding partners. Our findings highlight a novel mechanism for autosomal-dominant primary immunodeficiency through altered protein binding by mutant IRF4 at ISRE, leading to defective plasma cell differentiation.
- 14 February 2023
- Published by Wiley in British Journal of Haematology
- Vol. 201 (2) , 357-359
Reply to Zhou et al. ‘A novel approach for characterization of KSHV‐associated multicentric Castleman disease from effusions’
- 14 February 2023
- Published by Wiley in British Journal of Haematology
- Vol. 201 (2) , 357-359
Reply to Zhou et al. ‘A novel approach for characterization of KSHV‐associated multicentric Castleman disease from effusions’
- 1 December 2022
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 43 (10) , 10S26-10S33
Approche thérapeutique des maladies de Castleman : l’émergence des thérapies ciblées
- 1 December 2022
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 43 (10) , 10S26-10S33
Approche thérapeutique des maladies de Castleman : l’émergence des thérapies ciblées
- 12 October 2022
- Published by Wiley in British Journal of Haematology
- Vol. 199 (5) , 782-784
Mantle cell lymphoma in human immunodeficiency virus‐infected patients
- 12 October 2022
- Published by Wiley in British Journal of Haematology
- Vol. 199 (5) , 782-784
Mantle cell lymphoma in human immunodeficiency virus‐infected patients